# Sym004 Versus TAS-102 in Patients With mCRC

> **NCT03717038** · PHASE3 · WITHDRAWN · sponsor: **Symphogen A/S**

## Conditions studied

- Metastatic Colorectal Cancer
- Colorectal Cancer Metastatic
- Carcinoma

## Interventions

- **DRUG:** Sym004
- **DRUG:** TAS-102

## Key facts

- **NCT ID:** NCT03717038
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to administrative reasons
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717038, "Sym004 Versus TAS-102 in Patients With mCRC". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03717038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*